Unique to Central and Eastern Europe, the technology is the result of a 2 million euro investment made by MEDIREX. The installation of the new Aptio laboratory line was launched in November last year with the laboratories in full operation. Given the fact that the laboratories have to process tens of thousands of samples and the overall number of samples is constantly on a rise, the new line will make it possible to increase the speed and quality of sample analysis and shorten the period between the moments of sample arrival and test result delivery.
A major reason why the original LabCell line has been replaced by the Aptio line is the increasing number of biological material samples coming to the central laboratories. Another reason why the old line has been replaced with a new one is that a higher level of automation is required to cope with certain processes that were previously carried out by hand. The new line makes it possible to provide a wider spectrum of parameters by integrating analysers from various suppliers, bringing together biochemical, immunochemical, serological, haematological, immunological, and coagulation parameters into one analytical package. The new line was supplied by Siemens Healthineers.
ABOUT MEDIREX GROUP:
MEDIREX GROUP runs state-of-the-art laboratories that represent the cutting edge of laboratory diagnostics in Europe. Since its establishment, MEDIREX GROUP has repeatedly made considerable investments in laboratory technology and equipment – typically tens of millions of euros.
MEDIREX GROUP laboratories (Medirex, Medicyt) are the largest providers of laboratory diagnostics in Slovakia, ensuring complex diagnostics in a variety of fields, including clinical biochemistry, haematology, immunology, medical genetics, cytology, histology, bacteriology, mycology, parasitology, virology, serology, molecular biology, and environmental microbiology.